Alector, Inc.

Alector, Inc. is a clinical-stage biotechnology company that discovers and develops therapies for neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Lewy body dementia. The company utilizes its proprietary blood-brain barrier delivery technology, called Alector Brain Carrier, to transport antibodies, enzymes, and siRNA molecules into the central nervous system. Its clinical pipeline features nivisnebart, an investigational antibody undergoing clinical evaluation for early Alzheimer's disease in collaboration with GlaxoSmithKline. Preclinical candidates include an anti-amyloid beta antibody, an enzyme replacement therapy, and genetic therapies targeting tau, alpha-synuclein, and NLRP3. As a clinical-stage biopharmaceutical enterprise without commercialized therapies, its primary partners are pharmaceutical companies rather than commercial end customers.

The company maintains its principal executive offices and research laboratories in South San Francisco, California, along with additional facilities in Newark, California. Alector is incorporated under the laws of Delaware and manages international clinical trials across multiple regions, including the United States.

Summary of the business section of Alector's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we had 103 full-time employees, 70% of whom were engaged in research and development activities.”